Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...
Ozempic maker Novo Nordisk A/S is investing 8.5 billion kroner ($1.2 billion) to build a new major factory in Denmark to help ...
Novo Nordisk said the European Union’s drug regulator supports a label expansion of its Ozempic diabetes drug to reflect its ...
Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance ...
The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...
Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...
Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...
It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...